Roche Holding AG
SIX:ROG
Intrinsic Value
Roche Holding AG operates as a research healthcare company. [ Read More ]
The intrinsic value of one
ROG
stock under the Base Case scenario is
339.89
CHF.
Compared to the current market price of 221.3 CHF,
Roche Holding AG
is
Undervalued by 35%.
Roche Holding AG's market capitalization is 176.4B CHF.
ROG stock price is 221.3 CHF.
ROG stock price (221.3 CHF) is 35% less than its Intrinsic Value (339.89 CHF).
ROG stock price (221.3 CHF) is 32% less than its Relative Value (325.41 CHF). Open Relative Valuation
ROG has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
ROG's Revenue has been growing by 0% per year for the last 3 years.
ROG's ROIC (Return on Invested Capital) has decreased in the last 3 years from 23% to 23%.
ROG's ROE (Return on Equity) has decreased in the last 3 years from 41% to 40%.
ROG's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
ROG's Revenue has dropped by 7% over the past 12 months.
ROG's D/E (Debt to Equity) is very low and is equal to 0.89.
ROG's short-term assets (33B CHF) exceed its short-term liabilties (25B CHF).
ROG's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 23%.
ROG has positive Net Income for the last twelve months.
ROG's long-term assets (90B CHF) exceed its long-term liabilties (61B CHF).
ROG has positive Net Debt. This means that the company has more debt (26B CHF) than cash and short-term investments (11B CHF).
ROG has positive Operating Income for the last twelve months.
ROG has positive three-year average ROIC (Return on Invested Capital): 22%. The company is efficient at using invested capital to generate operating income.
ROG's ROE (Return on Equity) for the past 12 months is very high and is equal to 40%.
ROG has positive Free Cash Flow for the last twelve months.
ROG has positive Gross Profit for the last twelve months.
ROG's Altman Z-Score is very high and is equal to 3.91.
ROG has very high three-year average ROE (Return on Equity): 43%. The company is very efficient at transforming stockholders' equity into net income.
ROG earns more than enough operating income (19B CHF) to safely cover interest payments on its debt (770m CHF).
Valuation Backtest
Roche Holding AG
Run backtest to discover the historical profit from buying and selling
ROG
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Roche Holding AG
Balance Sheet Decomposition
Roche Holding AG
| Current Assets | 33.4B |
| Cash & Short-Term Investments | 10.5B |
| Receivables | 11.4B |
| Other Current Assets | 11.6B |
| Non-Current Assets | 57B |
| PP&E | 22.9B |
| Intangibles | 24.2B |
| Other Non-Current Assets | 9.9B |
| Current Liabilities | 24.8B |
| Accounts Payable | 4.3B |
| Short-Term Debt | 1.4B |
| Other Current Liabilities | 19.1B |
| Non-Current Liabilities | 36.3B |
| Long-Term Debt | 24.8B |
| Other Non-Current Liabilities | 11.5B |
Earnings Waterfall
Roche Holding AG
|
Revenue
|
58.7B
CHF
|
|
Cost of Revenue
|
-15.5B
CHF
|
|
Gross Profit
|
43.2B
CHF
|
|
Operating Expenses
|
-24B
CHF
|
|
Operating Income
|
19.2B
CHF
|
|
Other Expenses
|
-7.7B
CHF
|
|
Net Income
|
11.5B
CHF
|
Free Cash Flow Analysis
Roche Holding AG
ROG Profitability Score
Profitability Due Diligence
Roche Holding AG's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Roche Holding AG's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
ROG Solvency Score
Solvency Due Diligence
Roche Holding AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Roche Holding AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ROG Price Targets Summary
Roche Holding AG
According to Wall Street analysts, the average 1-year price target for
ROG
is 282.06 CHF
with a low forecast of 217.15 CHF and a high forecast of 445.2 CHF.
Shareholder Return
ROG Price
Roche Holding AG
| Average Annual Return | 6.34% |
| Standard Deviation of Annual Returns | 20.67% |
| Max Drawdown | -43% |
| Market Capitalization | 176.4B CHF |
| Shares Outstanding | 804 000 000 |
| Percentage of Shares Shorted |
N/A
|
ROG News
Last Important Events
Roche Holding AG
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Roche Holding AG
Company Profile
Roche Holding AG
Country
Industry
Market Cap
Dividend Yield
Description
Roche Holding AG operates as a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 100,920 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Contact
IPO
Employees
Officers
The intrinsic value of one
ROG
stock under the Base Case scenario is
339.89
CHF.
Compared to the current market price of 221.3 CHF,
Roche Holding AG
is
Undervalued by 35%.
You don't have any saved screeners yet
